U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

SRX24622324: GSM8283812: HL-60 BRD4 Panobinostat; Homo sapiens; OTHER
1 ILLUMINA (NextSeq 2000) run: 60.1M spots, 7.1G bases, 2.1Gb downloads

External Id: GSM8283812_r1
Submitted by: CIMA
Study: Novel epigenetic based differentiation therapy for Acute Myeloid Leukemia
show Abstracthide Abstract
Despite the development of novel therapies for acute myeloid leukemia (AML), outcomes remain poor for most patients, and therapeutic improvements are an urgent unmet need. Although treatment regimens promoting differentiation have succeeded in the treatment of acute promyelocytic leukemia (APL), their role in other AML subtypes needs to be explored. Here we identified and characterized two lysine (K) deacetylase inhibitors (DACi), CM-444 and CM-1758, exhibiting capacity to promote myeloid differentiation in all AML subtypes at low non-cytotoxic doses unlike other commercial HDACi. Analyzing the acetylome after CM-444 and CM-1758 treatment revealed modulation of non-histone proteins involved in the enhancer–promoter chromatin regulatory complex, including bromodomain proteins (BRDs). This acetylation was essential for enhancing the expression of key transcription factors directly involved in the differentiation therapy induced by CM-444/CM-1758 in AML. In summary, these compounds may represent effective differentiation-based therapeutic agents across AML subtypes with a novel mechanism for treatment of AML. Overall design: Epigenetic small molecules like CM-444, compared to commercial differentiation agents like panobinostat, used for AML differentiation.
Sample: HL-60 BRD4 Panobinostat
SAMN41474904 • SRS21359460 • All experiments • All runs
Organism: Homo sapiens
Library:
Name: GSM8283812
Instrument: NextSeq 2000
Strategy: OTHER
Source: GENOMIC
Selection: other
Layout: PAIRED
Construction protocol: CUT&RUN was performed with the kit CUTANA ChIC/CUT&RUN (Epicypher, 14-1048) following the manufacturer's instructions. Briefly, 0.5 million of HL-60 cells were harvested and resuspended in 100ul wash buffer [20 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM Spermidine, supplemented with Protease Inhibitor EDTA-Free tablet (Roche 11836170001)]. Activated Concanavalin A was incubated with cells at room temperature for 10min to let the cells bind to the beads. For each target protein factor, 0.5μg of BRD4 CUTANA CUT&RUN antibody (Cat No 13-2003, Epicypher), Acetyl-Histone H3 (Lys 9) (C5B11) rabbit monoclonal antibody diluted 1:50 (Cat No 9649T, Cell Signaling) or Acetyl-Histone H3 (Lys 27) (D5E4) XP rabbit monoclonal antibody diluted 1:100 (Cat No 8173T, Cell Signaling) was added to each sample and incubated in the antibody buffer (wash buffer +0.01% Digitonin and 2 mM EDTA) overnight at 4°C. Isotype control IgG was used as a negative control. The beads were then washed twice with digitonin buffer [wash buffer +0.01% Digitonin], and 2.5 μL pAG-MNase was added to each sample. After ten minutes of incubation at room temperature, excessive pAG-MNase was washed out by a two-time digitonin buffer wash. Then targeted chromatin was digested and released from cells by 2 h of incubation with the presence of 2 mM CaCl2 at 4°C. After incubation with stop buffer [340 mM NaCl, 20 mM EDTA, 4 mM EGTA, 50 μg/mL RNase A, 50 μg/mL Glycogen] for 10 min at 37ºC the supernatant containing CUT&RUN-enriched DNA was purified using the CUTANA DNA Purification kit (Epicypher). Illumina sequencing libraries were prepared from 6 ng of purified CUT&RUN DNA using NEBNext UltraTM II DNA Library Prep Kit for Illumina, following the manufacturer's instructions. For BRD4, some modifications were added following the protocol of Nan Liu (Harvard University; https://dx.doi.org/10.17504/protocols.io.wvgfe3w).
Runs: 1 run, 60.1M spots, 7.1G bases, 2.1Gb
Run# of Spots# of BasesSizePublished
SRR2909826860,090,4127.1G2.1Gb2024-05-21

ID:
32941180

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...